

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

			www.tispto.gov	
774175.18		DIVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
BIRCH STEV	FILING DATE 08/02/2001 590 05/21/2002 VART KOLASCH & .CH, VA 22040-0747		O020-4883P EXAM JAGOE, E ART UNIT 1614 DATE MAILED: 05/21/200	PAPER NUMBER
			DATE MAILLED.	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/890,552	YOKOYAMA ET AL.
arra Action Cummary	Examiner	Art Unit
Office Action Summary	l	1614
The MAILING DATE of this communication	appears on the cover sh	eet with the correspondence address
The MAILING DATE of this communication priod for Reply	••	THE PROPERTY OF THE PROPERTY O
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, - If NO period for reply is specified above, the maximum statutory proportion of the period for reply within the set or extended period for reply will, by the Any reply received by the Office later than three months after the seamed patent term adjustment. See 37 CFR 1.704(b).	R 1.136(a). In no event, nowever n. a reply within the statutory minimulariod will apply and will expire SIX statute, cause the application to be mailing date of this communication	im of thirty (30) days will be considered timely. (6) MONTHS from the mailing date of this communication.
Despensive to communication(s) filed or	··	
		al.
closed in accordance with the practice a	allowance except for for Inder Ex parte Quayle, 1	mal matters, prosecution as to the merits is 935 C.D. 11, 453 O.G. 213.
o:esition of Claims		
4) Claim(s) 1-8 and 11-17 is/are pending in	thdrawn from considera	tion.
4a) Of the above claim(s) is/are wi	miniawii iioiii oono.co.c	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-8 and 11-17</u> is/are rejected.		
is/are objected to.	de alaction roquire	ment.
8) Claim(s) are subject to restriction	and/or election require	
Application Papers		
9) The specification is objected to by the Ex	canniner. Decembed or h\□ object	ed to by the Examiner.
9) The specification is objected to by the 25 10) The drawing(s) filed on is/are: a) Applicant may not request that any objection	accepted of b/L_1 bejood	ld in abeyance. See 37 CFR 1.85(a).
Applicant may not request that any objecti 11) The proposed drawing correction filed or	on to the drawing(s) bornov	ed b) disapproved by the Examiner.
11)☐ The proposed drawing correction filed of	red in reply to this Office at	tion.
If approved, corrected drawings are require	ed in teply to also office a	
12) The oath or declaration is objected to by	WIE EXCITITION	
Priority under 35 U.S.C. §§ 119 and 120	contraction and a second or 3	5 U.S.C. § 119(a)-(d) or (f).
13) Acknowledgment is made of a claim to	r roreign priority under c	
None of:		
de	ocuments have been rec	paived in Application No
ملسينه في المسترين ا	soumonte have neen rev	Celved III / Ppilotine
3. Copies of the certified copies of application from the Internal	the priority documents tional Bureau (PCT Rule	e 17.2(a)). conies not received.
l and a claim for	domestic priority under	00 5.5.5.5
a) The translation of the foreign lang	nuage provisional applic	ation has been received.
15) Acknowledgment is made of a claim to	M dollloons bus	
Attachment(s)	4)	Interview Summary (PTO-413) Paper No(s)
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO-1449) Page 1	ro-948) 5)	Notice of Informal Patent Application (PTO-152) Other:
3) 🖂 IIIIOITIAIOTI SIGGESTI		Part of Paper No. 10

Art Unit: 1614

Claims 1-8 and 11-17 are pending in this application.

Information Disclosure Statement

The information disclosure statement filed November 2, 2002 fails to comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609 because there is not an english translation of english language abstract. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609 ¶ C(1).

Response to Arguments

Rejection of claims 14-16 under 35 U.S.C. § 112 1st paragraph is no longer maintained in view of the amendment.

The Examiner is in agreement with the persuasive remarks submitted concerning the outstanding 35 U.S.C. 112 2nd paragraph rejection in paper number 6 with regard to claims 4-8 in view of which the rejection is hereby withdrawn.

However, the rejection made in paper number 6 over claims 14-16under 35 U.S.C. §112 2nd paragraph is maintained and is hereby repeated. While the term "hydrophilic high molecular weight compound" is defined in the specification with regard

to the patch formulation, there is no guidance in the specification with regard to any examples of "hydrophilic high molecular weight compounds" that may be employed with the ointment formulation. It is suggested that the applicant recite a range for example "hydrophilic high molecular weight compounds having a molecular weight of from x to x Daltons".

Applicant's arguments filed February 28, 2002 have been fully considered but they are not persuasive.

Claim Rejections - 35 USC § 102

The rejection made in paper number 6 over Yoshida et al. under 35 U.S.C.
 §102(b) is maintained and is hereby repeated.

Applicant argues that the term "thermogenic sheet-combined poultice" is not a patch and asserts that the invention is not intended for use as a drug. The examiner is not in agreement. The broad definition of the word "patch" is a piece of material. Since a "thermogenic sheet-combined poultice" would still be applied as a "patch", it meets the claim. Applicant further asserts that Yoshida et al. is directed to heat therapy using a thermogenic sheet combined poultice. Applicant does not exclude the use of heat by the broad claim language "comprising" which leaves the claim open for the inclusion of unspecified ingredients, even in major amounts and as such, does not exclude thermogenic combined poultice.

2. The rejection made in paper number 6 over Noda et al. under 35 U.S.C. §102(b) is maintained and is hereby repeated.

Applicant asserts that Noda et al. does not teach I-menthol and peppermint oil as an active ingredient for alleviating a migraine. Applicant's claim is drawn to a composition of matter. The intended use of the claimed composition does not patentably distinguish the composition, per se, since such undisclosed use is inherent in the reference composition.

3. The rejection made in paper number 6 over Block et al. under 35 U.S.C. §102(b) is maintained and is hereby repeated.

Applicant asserts that Block et al. does not teach the active ingredients must be I-menthol and one or more essential oils. In response, "Products of identical chemical composition (i.e. menthol) can not have mutually exclusive properties." A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims (i.e. relief of headaches) are necessarily present. In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) (Applicant argued that the claimed composition was a pressure sensitive adhesive containing a tacky polymer while the product of the reference was hard and abrasion resistant. "The Board correctly found that the virtual identity of monomers and procedures sufficed to support a prima facie case of unpatentability of Spada's polymer latexes for lack of novelty." Applicant asserts that Block et al. teaches that the preferred embodiments contain components other than the

Art Unit: 1614

active ingredients claimed in the instant application (I-menthol and one or more essential oils). In response, Block et al. teach, in a preferred embodiment, menthol, and the essential oils, spirits of turpentine, eucalyptus oil and camphor. The humectant is a high molecular weight substance and the thickener is the polyhydric alcohol. Thus Block et al. encompasses the claims of the instant application.

Claim Rejections - 35 USC § 103

The rejection made in paper number 6 over Barr et al. under 35 U.S.C.
 §103(a) is maintained and is hereby repeated.

Applicant asserts that Barr et al. uses capsaicin as an active ingredient and does not use I-menthol as the active ingredient. In response, the claim language *comprising* leaves the claim open for the inclusion of unspecified ingredients, even in major amounts. The claims of the instant application do not exclude capsaicin.

(New) Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 17 is rejected under 35 U.S.C. 102(b) as being anticipated by Noda et al. U.S. Patent No. 5,519,046.

The claim is drawn to a composition wherein the amounts of I-menthol and one or more essential oils are 0.01%-1% by weight per total weight of the base and 0.001-1% per total weight of the base respectively.

Noda et al. teach menthol in a proportion of from 0.01% to 10% by weight which would encompass the claimed range of the instant claim.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna A. Jagoe whose telephone number is (703) 306-5826. The examiner can normally be reached on 6:30 A.M. - 3 P.M..

Application/Control Number: 09/890,552

Art Unit: 1614

Page 7

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3230 for regular communications and (703) 308-7921 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0193.

dj

May 19, 2002

THE SECOND TO SECOND THE SECOND TO S